TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 0.900nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 2.40nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 5nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 6nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 6nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 6nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 9nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 17nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 20nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 25nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 26nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 29nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 29nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 30nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 31nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 39nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 49nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 55nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 59nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 68nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 73nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 74nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 78nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 80nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 80nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 123nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 126nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 151nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
TargetLipopolysaccharide-induced tumor necrosis factor-alpha factor(Homo sapiens (Human))
Vtv Therapeutics
US Patent
Vtv Therapeutics
US Patent
Affinity DataIC50: 163nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair